# Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

> **NCT03201250** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Nebraska** · enrollment: 11 (actual)

## Conditions studied

- Multiple Myeloma
- Refractory Multiple Myeloma
- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT03201250
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-21
- **Primary completion:** 2021-04-12
- **Final completion:** 2021-04-12
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Phase I response to treatment was not as expected and the myeloma field in treatment has changed since initiating the study, so investigators felt the study should not be pursued into Phase II.
- **Last updated:** 2023-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201250, "Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03201250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*